Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study

被引：0
|
作者：
Iglesias Docampo, L. [1 ]
Baste Rotllan, N. [2 ]
Oliva Bernal, M. [3 ]
Carral Maseda, A. [4 ]
Perez Segura, P. [5 ]
Medina Colmenero, A. [6 ]
Cirauqui Cirauqui, B. [7 ]
Arrazubi Arrula, V. [8 ]
Martinez Trufero, J. [9 ]
Gutierrez Calderon, V. [10 ]
Garcia Castano, A. [11 ]
Rubio-Casadevall, J. [12 ]
Basterretxea, L. [13 ]
Alvarez Cabellos, R. [14 ]
del Barco Morillo, E. [15 ]
Bruixola, G. [16 ]
Flor, M. J. [17 ]
Assaf Pastrana, J. D. [18 ]
Caballero Daroqui, J. [19 ]
Mesia Nin, R. [20 ]
机构：
[1] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain
[2] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[3] Hosp Duran & Reynals, ICO Inst Catala Oncol Hospitalet, Med Oncol, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Lucus Augusti HULA, Med Oncol, Lugo, Spain
[5] Hosp Clin Univ San Carlos, Med Oncol, IdISSC, Madrid, Spain
[6] Fdn Ctr Oncol Galicia, Med Oncol, La Coruna, Spain
[7] Hosp Badalona Germans Trias & Pujol, Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Barcelona, Spain
[8] Hosp Univ Navarra, Navarra Inst Hlth Res, Med Oncol, IdiSNA, Pamplona, Spain
[9] Hosp Univ Miguel Servet, Med Oncol, Zaragoza, Spain
[10] Hosp Reg Univ Malaga, Med Oncol, Malaga, Spain
[11] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain
[12] ICO Girona Inst Catala Oncol Girona, Med Oncol, Girona, Spain
[13] Hosp Univ Donostia, Med Oncol, Donostia San Sebastian, Spain
[14] Hosp Univ Toledo, Med Oncol, Toledo, Spain
[15] Complejo Hosp Salamanca IBSAL, Med Oncol, Salamanca, Spain
[16] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain
[17] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain
[18] Hosp Univ Vall dHebron, Med Oncol, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[19] Hosp Univ & Politecn La Fe, Med Oncol, Valencia, Spain
[20] Hosp Badalona Germans Trias & Pujol, Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.932
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
871P
引用
收藏
页码：S624 / S624
页数：1
相关论文
共 50 条
  • [41] A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy
    Zandberg, D. P.
    Chen, J.
    Tatsuoka, C.
    Normolle, D. P.
    Ohr, J.
    Isett, B.
    Rahman, Z.
    Fenton, M.
    Gooding, W.
    Vujanovic, L.
    Bao, R.
    Marsh, C.
    Seastone, D.
    Gorantla, V.
    Pabla, S.
    Conroy, J.
    Ferris, R. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E4 - E4
  • [42] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Bossi, P.
    Miceli, R.
    Locati, L. D.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Denaro, N.
    Caponigro, F.
    Airoldi, M.
    Moro, C.
    Vaccher, E.
    Sponghini, A.
    Caldara, A.
    Rinaldi, G.
    Ferrau, F.
    Nole, F.
    Lo Vullo, S.
    Tettamanzi, F.
    Hollander, L.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2820 - 2826
  • [43] Phase II trial of irinotecan (Ir) plus cisplatin (CDDP) in patients with recurrent or metastatic squamous carcinoma of the head and neck (SCCHN)
    Gilbert, J.
    Cmelak, A.
    Burkey, B.
    Sinard, R.
    Yarborough, W.
    Netterville, J.
    Paty, V.
    Chung, C.
    Hudson, T.
    Murphy, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
    Vermorken, J. B.
    Licitra, L.
    Stoehlmacher-Williams, J.
    Dietz, A.
    Lopez-Picazo, J. M.
    Hamid, O.
    Hossain, A. M.
    Chang, S. -C.
    Gauler, T. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2877 - 2883
  • [45] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
    Scheff, Nicole N.
    Nilsen, Marci Lee
    Li, Jinhong
    Harris, Alexandria L.
    Swartz, Andrew
    Hsieh, Ronan Wenhan
    Anderson, Jennifer Lynn
    Ferris, Robert L.
    Menk, Ashley
    Delgoffe, Greg M.
    Zandberg, Dan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Chow, Laura Quan Man
    Mehra, Ranee
    Haddad, Robert I.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Ayers, Mark
    Aurora-Garg, Deepti
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] PHASE-II TRIAL OF CARBOPLATIN PLUS CISPLATIN IN RECURRENT AND ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    DIMERY, IW
    BROOKS, BJ
    WINN, R
    MARTIN, T
    SHIRINIAN, M
    HONG, WK
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (11) : 1939 - 1944
  • [48] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
  • [49] Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
    Caponigro, Francesco
    Di Gennaro, Elena
    Ionna, Franco
    Longo, Francesco
    Aversa, Corrado
    Pavone, Ettore
    Maglione, Maria Grazia
    Di Marzo, Massimiliano
    Muto, Paolo
    Cavalcanti, Ernesta
    Petrillo, Antonella
    Sandomenico, Fabio
    Maiolino, Piera
    D'Aniello, Roberta
    Botti, Gerardo
    De Cecio, Rossella
    Losito, Nunzia Simona
    Scala, Stefania
    Trotta, Annamaria
    Zotti, Andrea Ilaria
    Bruzzese, Francesca
    Daponte, Antonio
    Calogero, Ester
    Montano, Massimo
    Pontone, Monica
    De Feo, Gianfranco
    Perri, Francesco
    Budillon, Alfredo
    BMC CANCER, 2016, 16
  • [50] Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
    Francesco Caponigro
    Elena Di Gennaro
    Franco Ionna
    Francesco Longo
    Corrado Aversa
    Ettore Pavone
    Maria Grazia Maglione
    Massimiliano Di Marzo
    Paolo Muto
    Ernesta Cavalcanti
    Antonella Petrillo
    Fabio Sandomenico
    Piera Maiolino
    Roberta D’Aniello
    Gerardo Botti
    Rossella De Cecio
    Nunzia Simona Losito
    Stefania Scala
    Annamaria Trotta
    Andrea Ilaria Zotti
    Francesca Bruzzese
    Antonio Daponte
    Ester Calogero
    Massimo Montano
    Monica Pontone
    Gianfranco De Feo
    Francesco Perri
    Alfredo Budillon
    BMC Cancer, 16
12345